Products from BPS Bioscience require a minimum order value above 400€
Applications: This kit is useful for screening for inhibitors of CTLA4 binding to B7-2.
Background: B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit Tcell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancersto escape the host's immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy)and Tremelimumab, have shown clinical efficacy in treating cancer.
Description: The CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, B7-2 is coated on a 96-well plate. Next, CTLA4-biotin is incubated with B7-2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.
Storage Stability: Stable at least 6 months from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival
Supplied As: This kit comes in a convenient 96- well format, with biotin-labeled CTLA4 (CD152), purified B7-2 (CD86), streptavidin-labeled HRP, and assay buffer for 100 binding reactions
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Ohtani, H., et al., Lab Invest. 1997; 77(3): 231-241.
2. Rovert, C., et al., N. Engl. J. Med. 2011; 364: 2517-25262.
English
Deutsch
